{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:08:13Z","timestamp":1790564893444,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Definitive chemoradiotherapy (dCRT) is a standard treatment for patients with locally advanced head and neck cancer. There is a clinical need for a stratification of this prognostically heterogeneous group of tumors in order to optimize treatment of individual patients. We retrospectively reviewed all patients with head and neck squamous cell carcinoma (HNSCC) of the oral cavity, oropharynx, hypopharynx, or larynx, treated with dCRT from 09\/2008 until 03\/2016 at the Department of Radiation Oncology, LMU Munich. Here we report the clinical results of the cohort which represent the basis for biomarker discovery and molecular genetic research within the framework of a clinical cooperation group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patient data were collected and analyzed for outcome and treatment failures with regard to previously described and established risk factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 184 patients with a median follow-up of 65\u2009months and a median age of 64\u2009years. Patients received dCRT with a median dose of 70\u2009Gy and simultaneous chemotherapy in 90.2% of cases, mostly mitomycin C \/ 5-FU in concordance with the ARO 95\u201306 trial. The actuarial 3-year overall survival (OS), local, locoregional and distant failure rates were 42.7, 29.8, 34.0 and 23.4%, respectively. Human papillomavirus-associated oropharynx cancer (HPVOPC) and smaller gross tumor volume were associated with significantly improved locoregional tumor control rate, disease-free survival (DFS) and OS in multivariate analysis. Additionally, lower hemoglobin levels were significantly associated with impaired DFS und OS in univariate analysis. The extent of lymph node involvement was associated with distant failure, DFS and OS. Moreover, 92 patients (50%) of our cohort have been treated in concordance with the ARO 95\u201306 study, corroborating the results of this study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our cohort is a large unselected monocentric cohort of HNSCC patients treated with dCRT. Tumor control rates and survival rates compare favorably with the results of previously published reports. The clinical data, together with the available tumor samples from biopsies, will allow translational research based on molecular genetic analyses.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-019-1452-4","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T16:02:43Z","timestamp":1578326563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group \u201cPersonalized Radiotherapy in Head and Neck Cancer\u201d"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3305-3806","authenticated-orcid":false,"given":"Lars","family":"Sch\u00fcttrumpf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Marschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Scheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Rietzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Walch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Baumeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Ganswindt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Zitzelsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius","family":"Maihoefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,6]]},"reference":[{"key":"1452_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pi\u00f1eros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941\u201353.","journal-title":"Int J Cancer"},{"key":"1452_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.radonc.2011.05.036","volume":"100","author":"P Blanchard","year":"2011","unstructured":"Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol Elsevier Ireland Ltd. 2011;100:33\u201340.","journal-title":"Radiother Oncol Elsevier Ireland Ltd"},{"key":"1452_CR3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.radonc.2016.11.008","volume":"121","author":"A Linge","year":"2016","unstructured":"Linge A, Lohaus F, L\u00f6ck S, Nowak A, Gudziol V, Valentini C, et al. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: a multicentre retrospective study of the German Cancer consortium radiation. Radiother Oncol. Elsevier Ireland Ltd. 2016;121:364\u201373.","journal-title":"Radiother Oncol. Elsevier Ireland Ltd"},{"key":"1452_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.radonc.2017.10.018","volume":"126","author":"P Lassen","year":"2018","unstructured":"Lassen P, Lacas B, Pignon J-P, Trotti A, Zackrisson B, Zhang Q, et al. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project. Radiother Oncol. Elsevier B.V. 2018;126:107\u201315.","journal-title":"Radiother Oncol. Elsevier B.V"},{"key":"1452_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/1471-2407-14-187","volume":"14","author":"DH Maasland","year":"2014","unstructured":"Maasland DH, van den Brandt PA, Kremer B, Goldbohm RA, Schouten LJ. Alcohol consumption, cigarette smoking and the risk of subtypes of head-neck cancer: results from the Netherlands cohort study. BMC Cancer. 2014;14:187.","journal-title":"BMC Cancer"},{"key":"1452_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/bjc.2015.111","volume":"113","author":"I Summerer","year":"2015","unstructured":"Summerer I, Unger K, Braselmann H, Schuettrumpf L, Maihoefer C, Baumeister P, et al. Circulating microRNAs as prognostic therapy biomarkers in head and neck cancer patients. Br J Cancer. 2015;113:76\u201382.","journal-title":"Br J Cancer"},{"key":"1452_CR7","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1002\/1878-0261.12388","volume":"12","author":"L Wintergerst","year":"2018","unstructured":"Wintergerst L, Selmansberger M, Maihoefer C, Sch\u00fcttrumpf L, Walch A, Wilke C, et al. A prognostic mRNA expression signature of four 16q24.3 genes in radio(chemo)therapy-treated head and neck squamous cell carcinoma (HNSCC). Mol Oncol. 2018;12:2085\u2013101.","journal-title":"Mol Oncol"},{"key":"1452_CR8","doi-asserted-by":"publisher","first-page":"14582","DOI":"10.1038\/s41598-018-32178-8","volume":"8","author":"P Baumeister","year":"2018","unstructured":"Baumeister P, Hollmann A, Kitz J, Afthonidou A, Simon F, Shakhtour J, et al. High expression of EpCAM and Sox2 is a positive prognosticator of clinical outcome for head and neck carcinoma. Sci Rep. 2018;8:14582.","journal-title":"Sci Rep"},{"key":"1452_CR9","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1158\/1078-0432.CCR-18-0776","volume":"25","author":"J Hess","year":"2019","unstructured":"Hess J, Unger K, Maihoefer C, Sch\u00fcttrumpf L, Wintergerst L, Heider T, et al. A five-MicroRNA signature predicts survival and disease control of patients with head and neck Cancer negative for HPV infection. Clin Cancer Res. 2019;25:1505\u201316.","journal-title":"Clin Cancer Res"},{"key":"1452_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-016-0740-5","volume":"12","author":"G Vlacich","year":"2017","unstructured":"Vlacich G, Stavas MJ, Pendyala P, Chen SC, Shyr Y, Cmelak AJ. A comparative analysis between sequential boost and integrated boost intensity-modulated radiation therapy with concurrent chemotherapy for locally-advanced head and neck cancer. Radiat Oncol Radiation Oncology. 2017;12:1\u20139.","journal-title":"Radiat Oncol Radiation Oncology"},{"key":"1452_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.radonc.2015.10.014","volume":"118","author":"W Budach","year":"2016","unstructured":"Budach W, B\u00f6lke E, Kammers K, Gerber PA, Orth K, Gripp S, et al. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): a meta-analysis of randomized trials. Radiother Oncol. 2016;118:238\u201343.","journal-title":"Radiother Oncol"},{"key":"1452_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1470-2045(11)70346-1","volume":"13","author":"J Bourhis","year":"2012","unstructured":"Bourhis J, Sire C, Graff P, Gr\u00e9goire V, Maingon P, Calais G, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol. 2012;13:145\u201353.","journal-title":"Lancet Oncol"},{"key":"1452_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13014-018-1133-8","volume":"13","author":"C Matuschek","year":"2018","unstructured":"Matuschek C, Haussmann J, B\u00f6lke E, Gripp S, Schuler PJ, Tamaskovics B, et al. Accelerated vs. conventionally fractionated adjuvant radiotherapy in high-risk head and neck cancer: a meta-analysis. Radiat Oncol. 2018;13:195.","journal-title":"Radiat Oncol"},{"key":"1452_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","volume":"21","author":"DJ Adelstein","year":"2003","unstructured":"Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent Chemoradiotherapy in patients with Unresectable squamous cell head and neck Cancer. J Clin Oncol. 2003;21:92\u20138.","journal-title":"J Clin Oncol"},{"key":"1452_CR15","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2005.07.010","volume":"23","author":"V Budach","year":"2005","unstructured":"Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, et al. Hyperfractionated accelerated Chemoradiation with concurrent fluorouracil-Mitomycin is more effective than dose-escalated Hyperfractionated accelerated radiation therapy alone in locally advanced head and neck Cancer: final results of the radiotherapy coo. J Clin Oncol. 2005;23:1125\u201335.","journal-title":"J Clin Oncol"},{"key":"1452_CR16","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ijrobp.2014.12.034","volume":"91","author":"V Budach","year":"2015","unstructured":"Budach V, Stromberger C, Poettgen C, Baumann M, Budach W, Grabenbauer G, et al. Hyperfractionated Accelerated Radiation Therapy (HART) of 70.6 Gy With Concurrent 5-FU\/Mitomycin C Is Superior to HART of 77.6 Gy Alone in Locally Advanced Head and Neck Cancer: Long-term Results of the ARO 95\u201306 Randomized Phase III Trial. Int J Radiat Oncol. Elsevier Inc. 2015;91:916\u201324.","journal-title":"Int J Radiat Oncol. Elsevier Inc."},{"key":"1452_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","volume":"92","author":"J-P Pignon","year":"2009","unstructured":"Pignon J-P, le Ma\u00eetre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. Elsevier Ireland Ltd. 2009;92:4\u201314.","journal-title":"Radiother Oncol. Elsevier Ireland Ltd"},{"key":"1452_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13014-019-1235-y","volume":"14","author":"S Helfenstein","year":"2019","unstructured":"Helfenstein S, Riesterer O, Meier UR, Papachristofilou A, Kasenda B, Pless M, et al. 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck \u2013 a multicentre, retrospective analysis. Radiat Oncol. 2019;14:32.","journal-title":"Radiat Oncol"},{"key":"1452_CR19","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00066-018-1309-z","volume":"194","author":"T Carp\u00e9n","year":"2018","unstructured":"Carp\u00e9n T, Saarilahti K, Haglund C, Markkola A, Tarkkanen J, Hagstr\u00f6m J, et al. Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy. Strahlentherapie und Onkol. 2018;194:759\u201370.","journal-title":"Strahlentherapie und Onkol"},{"key":"1452_CR20","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1097\/01.mlg.0000240263.05198.a0","volume":"116","author":"S Oosterkamp","year":"2006","unstructured":"Oosterkamp S, de Jong JMA, Van Den Ende PL, Manni JJ, Dehing-Oberije C, Kremer B. Predictive value of lymph node metastases and Extracapsular extension for the risk of distant metastases in laryngeal carcinoma. Laryngoscope. 2006;116:2067\u201370.","journal-title":"Laryngoscope."},{"key":"1452_CR21","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1007\/s00405-016-4170-7","volume":"273","author":"H Suzuki","year":"2016","unstructured":"Suzuki H, Matoba T, Hanai N, Nishikawa D, Fukuda Y, Koide Y, et al. Lymph node ratio predicts survival in hypopharyngeal cancer with positive lymph node metastasis. Eur Arch Otorhinolaryngol. 2016;273:4595\u2013600.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"1452_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13014-015-0490-9","volume":"10","author":"C-C Chen","year":"2015","unstructured":"Chen C-C, Lin J-C, Chen K-W. Lymph node ratio as a prognostic factor in head and neck cancer patients. Radiat Oncol. 2015;10:181.","journal-title":"Radiat Oncol"},{"key":"1452_CR23","doi-asserted-by":"publisher","first-page":"vii167","DOI":"10.1093\/annonc\/mdq284","volume":"21","author":"M Dicato","year":"2010","unstructured":"Dicato M, Plawny L, Diederich M. Anemia in cancer. Ann Oncol. 2010;21:vii167\u201372.","journal-title":"Ann Oncol"},{"key":"1452_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1751-553X.2008.01067.x","volume":"30","author":"AJ Leifert","year":"2008","unstructured":"Leifert AJ. Anaemia and cigarette smoking. Int J Lab Hematol. 2008;30:177\u201384.","journal-title":"Int J Lab Hematol"},{"key":"1452_CR25","first-page":"114","volume":"35","author":"H Jager-Wittenaar","year":"2017","unstructured":"Jager-Wittenaar H, Dijkstra PU, Dijkstra G, Bijzet J, Langendijk JA, van der Laan B, et al. High prevalence of cachexia in newly diagnosed head and neck cancer patients: an exploratory study. Nutrition Elsevier Ltd. 2017;35:114\u20138.","journal-title":"Nutrition Elsevier Ltd"},{"key":"1452_CR26","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s00066-016-0999-3","volume":"192","author":"P Ghadjar","year":"2016","unstructured":"Ghadjar P, P\u00f6ttgen C, Joos D, Hayoz S, Baumann M, Bodis S, et al. Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers. Strahlentherapie und Onkol. 2016;192:552\u201360.","journal-title":"Strahlentherapie und Onkol."},{"key":"1452_CR27","doi-asserted-by":"publisher","first-page":"e0205712","DOI":"10.1371\/journal.pone.0205712","volume":"13","author":"P Baumeister","year":"2018","unstructured":"Baumeister P, Canis M, Reiter M. Preoperative anemia and perioperative blood transfusion in head and neck squamous cell carcinoma. PLoS One. 2018;13:e0205712 Goubran H, editor.","journal-title":"PLoS One"},{"key":"1452_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/lary.24847","volume":"125","author":"D Danan","year":"2015","unstructured":"Danan D, Smolkin ME, Varhegyi NE, Bakos SR, Jameson MJ, Shonka DC. Impact of blood transfusions on patients with head and neck cancer undergoing free tissue transfer. Laryngoscope. 2015;125:86\u201391.","journal-title":"Laryngoscope."},{"key":"1452_CR29","doi-asserted-by":"publisher","first-page":"50781","DOI":"10.18632\/oncotarget.9549","volume":"7","author":"MG Bredell","year":"2016","unstructured":"Bredell MG, Ernst J, El-Kochairi I, Dahlem Y, Ikenberg K, Schumann DM. Current relevance of hypoxia in head and neck cancer. Oncotarget. 2016;7:50781\u2013804.","journal-title":"Oncotarget."},{"key":"1452_CR30","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.radonc.2017.04.019","volume":"123","author":"M Christiaens","year":"2017","unstructured":"Christiaens M, Collette S, Overgaard J, Gregoire V, Kazmierska J, Castadot P, et al. Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV\/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure. Radiother Oncol. 2017;123:424\u201330 Elsevier B.V.","journal-title":"Radiother Oncol"},{"key":"1452_CR31","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S1470-2045(13)70181-5","volume":"14","author":"JB Vermorken","year":"2013","unstructured":"Vermorken JB, St\u00f6hlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14:697\u2013710.","journal-title":"Lancet Oncol."},{"key":"1452_CR32","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus Cetuximab in head and neck Cancer. N Engl J Med. 2008;359:1116\u201327.","journal-title":"N Engl J Med"},{"key":"1452_CR33","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1200\/JCO.2015.62.5970","volume":"34","author":"DI Rosenthal","year":"2016","unstructured":"Rosenthal DI, Harari PM, Giralt J, Bell D, Raben D, Liu J, et al. Association of Human Papillomavirus and p16 status with outcomes in the IMCL-9815 phase III registration trial for patients with Locoregionally advanced Oropharyngeal squamous cell carcinoma of the head and neck treated with radiotherapy with or without C. J Clin Oncol. 2016;34:1300\u20138.","journal-title":"J Clin Oncol"},{"key":"1452_CR34","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","volume":"32","author":"KK Ang","year":"2014","unstructured":"Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus Cisplatin with or without Cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32:2940\u201350.","journal-title":"J Clin Oncol"},{"key":"1452_CR35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11864-017-0484-y","volume":"18","author":"SH Huang","year":"2017","unstructured":"Huang SH, O\u2019Sullivan B. Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Curr Treat Options in Oncol. 2017;18:40.","journal-title":"Curr Treat Options in Oncol"},{"key":"1452_CR36","first-page":"5","volume":"0","author":"H Mehanna","year":"2018","unstructured":"Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2018;0:5\u20137 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673618327521.","journal-title":"Lancet"},{"key":"1452_CR37","first-page":"1","volume":"0","author":"ML Gillison","year":"2018","unstructured":"Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2018;0:1\u201311 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014067361832779X.","journal-title":"Lancet"},{"key":"1452_CR38","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.radonc.2016.08.009","volume":"122","author":"D Nevens","year":"2017","unstructured":"Nevens D, Duprez F, Daisne JF, Dok R, Belmans A, Voordeckers M, et al. Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control. Radiother Oncol. 2017;122:171\u20137.","journal-title":"Radiother Oncol"},{"issue":"10","key":"1452_CR39","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/annonc\/mdz171","volume":"30","author":"T Seiwert","year":"2019","unstructured":"Seiwert T. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019;30(10):1673.","journal-title":"Ann Oncol"},{"key":"1452_CR40","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.2016.68.3300","volume":"35","author":"S Marur","year":"2017","unstructured":"Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, et al. E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly Cetuximab in patients with HPV-associated Resectable squamous cell carcinoma of the oropharynx\u2014 ECOG-ACRIN Cancer research group. J Clin Oncol. 2017;35:490\u20137.","journal-title":"J Clin Oncol"},{"key":"1452_CR41","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13014-018-1067-1","volume":"13","author":"C Maihoefer","year":"2018","unstructured":"Maihoefer C, Sch\u00fcttrumpf L, Macht C, Pflugradt U, Hess J, Schneider L, et al. Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck \u2013 clinical results from the cohort of the clinical cooperation group \u201cPersonalized Radiotherapy in Head and Neck Cancer\u201d. Radiat Oncol. 2018;13:123.","journal-title":"Radiat Oncol"},{"key":"1452_CR42","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S1470-2045(19)30410-3","volume":"20","author":"AC Nichols","year":"2019","unstructured":"Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol Elsevier Ltd. 2019;20:1349\u201359.","journal-title":"Lancet Oncol Elsevier Ltd"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-019-1452-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-019-1452-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-019-1452-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:30:54Z","timestamp":1609806654000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-019-1452-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,6]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1452"],"URL":"https:\/\/doi.org\/10.1186\/s13014-019-1452-4","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,6]]},"assertion":[{"value":"11 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"For data analysis and the retrospective analysis of HPV p16 in some of the patients an ethics approval and consent were obtained (Ethics committee of the medical faculty of the LMU Munich. 448\u201313; 459\u201313; 17\u2013116).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}